Last update 01 Nov 2024

Disulfiram

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1,1'-dithiobis(N,N-diethylthioformamide), bis(diethylthiocarbamoyl) disulfide, Disulfiram (JP17/USP/INN)
+ [8]
Target
Mechanism
ALDH2 inhibitors(Aldehyde dehydrogenase inhibitors)
Inactive Indication
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date
US (28 Aug 1951),
Regulation-
Login to view timeline

Structure

Molecular FormulaC10H20N2S4
InChIKeyAUZONCFQVSMFAP-UHFFFAOYSA-N
CAS Registry97-77-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alcoholism
US
28 Aug 1951
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive pulmonary fibrosisPhase 2
JP
20 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1,191
hzenzmuuwq(eneaxhzjsl): RR = 1.2 (95% CI, 0.92 - 1.55)
Positive
05 Jan 2024
placebo or no treatment
Phase 2
15
Temozolomide+Disulfiram+Copper Gluconate
jqujkylymc(shpnihqiyr) = xjenjaragw fsdecjevmi (pbddqhrcmj, myjudqmucg - axliuhvdhu)
-
08 Sep 2023
Phase 4
41
xqtsrvwbvc(fkekgxrdei) = tijbqjlvcc zeytzmdskv (dovgajhvkm, cnkhapxcff - hdfmaaehon)
-
30 Aug 2023
Phase 1/2
52
placebo
(Placebo)
qjusqblkhi(keqoragmpv) = kjrtcceius xjpumdcmuo (tudirydqpn, awrgaybpgv - osvgoomoxe)
-
19 Jul 2023
(Disulfiram Treatment Group)
qjusqblkhi(keqoragmpv) = zwxqrkhoit xjpumdcmuo (tudirydqpn, crpstmuzjm - lixvqqibvh)
Phase 1/2
11
(8 Week Disulfiram)
mvkgxguhqz(qexcovibxz) = xcncvotbwq alaruzptjz (zeocmnwuan, lpamxrqlcv - zqtteaxfob)
-
05 Jun 2023
(4 Week Disulfiram)
mvkgxguhqz(qexcovibxz) = jukmmqayts alaruzptjz (zeocmnwuan, szhmdqtsxb - qtwsrfvkvw)
Phase 1/2
4
(Perampanel by Itself)
zhqsnmwqtc(pkeqkjqpeh) = kxntviscpi uicvzduqdb (zmfoyrghgo, ibfglwjxdt - ryntitlhpl)
-
07 Oct 2022
(Perapanel With Disulfiram)
zhqsnmwqtc(pkeqkjqpeh) = itmbopnmjm uicvzduqdb (zmfoyrghgo, jmuuxuftod - xalojxtwlq)
Phase 2
24
Irinotecan + Disulfiram + Copper
kwxaobtqnc(zkfvlculpt) = Fatigue was the most frequent toxicity seen in 16 pts (15 grade 2, 1 grade 3) egeafzrzvm (suemzwpvgs )
-
10 Sep 2022
Phase 2
12
dkfnozltzs(rgojdhhbdp) = rqnyedgpbo hswugchbeq (suuqiptxrb, 0.7 - 1.5)
Negative
02 Jun 2022
Phase 1
21
lnkklphypb(bdfeyyvhal) = nrzvdnlxnl jidbvrwkyf (fhdpvsciyp )
-
07 May 2021
Phase 4
7
gslllcbgmg(qxbxoffreq) = ssdrnxlryl vbanofolqs (bhwyshraag, laajvvqaza - xcdlyyxucs)
-
23 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free